Oncology Drug Approval News Flash: Datopotamab deruxtecan (Datroway) Receives Accelerated FDA Approval for EGFR-mutated NSCLC
[FDA Accelerated Approval] Datroway by Daiichi Sankyo approved for EGFR-mutated non-small cell lung cancer (June 23, 2025) On June 23, 2025, the U.S. FDA granted accelerated approval to Datopotamab deruxtecan-dlnk (Datroway) for adults w...
